Heike Wulff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9306259/publications.pdf

Version: 2024-02-01

185	12,656	22153	26613
papers	citations	59 h-index	107 g-index

191	191	191	10483
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Channelopathy-causing mutations in the S45A/S45B and HA/HB helices of KCa2.3 and KCa3.1 channels alter their apparent Ca2+ sensitivity. Cell Calcium, 2022, 102, 102538.	2.4	7
2	Structureâ€“Activity Relationship Study of Subtype-Selective Positive Modulators of K_{Ca}2 Channels. Journal of Medicinal Chemistry, 2022, 65, 303-322.	6.4	9
3	The seizureâ€inducing plastic explosive <scp>RDX</scp> inhibits the Î± 1 Î² 2 Î³ 2 <scp> GABA _A </scp> receptor. Annals of Clinical and Translational Neurology, 2022, , .	3.7	5
4	Muscle Damage in Dystrophic mdx Mice Is Influenced by the Activity of Ca2+-Activated KCa3.1 Channels. Life, 2022, 12, 538.	2.4	2
5	Pose Classification Using Three-Dimensional Atomic Structure-Based Neural Networks Applied to Ion Channelâ€“Ligand Docking. Journal of Chemical Information and Modeling, 2022, 62, 2301-2315.	5.4	5
6	Discovery of Novel Activators of Large-Conductance Calcium-Activated Potassium Channels for the Treatment of Cerebellar Ataxia. Molecular Pharmacology, 2022, 102, 17-28.	2.3	9
7	Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model. BMJ Open Diabetes Research and Care, 2022, 10, e002777.	2.8	2
8	The erythroid K-Cl cotransport inhibitor [(dihydroindenyl)oxy]acetic acid blocks erythroid Ca²⁺-activated K⁺ channel KCNN4. American Journal of Physiology - Cell Physiology, 2022, 323, C694-C705.	4.6	2
9	KCa channel activation normalizes endothelial function in Type 2 Diabetic resistance arteries by improving intracellular Ca2+ mobilization. Metabolism: Clinical and Experimental, 2021, 114, 154390.	3.4	8
10	A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 2021, 589, 474-479.	27.8	221
11	Identification of the Functional Binding Site for the Convulsant Tetramethylenedisulfotetramine in the Pore of the Î±₂Î²₃Î³₂ GABA_A Receptor. Molecular Pharmacology, 2021, 99, 78-91.	2.3	7
12	Structure-Activity Relationship of Neuroactive Steroids, Midazolam, and Perampanel Toward Mitigating Tetramine-Triggered Activity in Murine Hippocampal Neuronal Networks. Toxicological Sciences, 2021, 180, 325-341.	3.1	5
13	ATP-evoked intracellular Ca2+ transients shape the ionic permeability of human microglia from epileptic temporal cortex. Journal of Neuroinflammation, 2021, 18, 44.	7.2	8
14	Unique molecular characteristics and microglial origin of Kv1.3 channelâ€“positive brain myeloid cells in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	25
15	Editorial: Venoms, Animal and Microbial Toxins. Frontiers in Pharmacology, 2021, 12, 706573.	3.5	0
16	The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca²⁺â€activated K_{Ca}3.1 channels. British Journal of Pharmacology, 2021, 178, 4891-4906.	5.4	8
17	The efficacy of Î³-aminobutyric acid type A receptor (GABA AR) subtype-selective positive allosteric modulators in blocking tetramethylenedisulfotetramine (TETS)-induced seizure-like behavior in larval zebrafish with minimal sedation. Toxicology and Applied Pharmacology, 2021, 426, 115643.	2.8	8
18	Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline. Journal of Molecular and Cellular Cardiology, 2021, 158, 163-177.	1.9	10

#	Article	IF	Citations
19	Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling. Channels, 2021, 15, 67-78.	2.8	17
20	The potassium channel Kv1.3 as a therapeutic target forÂimmunocytoprotection after reperfusion. Annals of Clinical and Translational Neurology, 2021, 8, 2070-2082.	3.7	9
21	Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels. Annual Review of Pharmacology and Toxicology, 2020, 60, 219-240.	9.4	69
22	SKA-31, an activator of Ca2+-activated K+ channels, improves cardiovascular function in aging. Pharmacological Research, 2020, 151, 104539.	7.1	13
23	Susceptibility of larval zebrafish to the seizurogenic activity of GABA type A receptor antagonists. NeuroToxicology, 2020, 76, 220-234.	3.0	35
24	Acute administration of diazepam or midazolam minimally alters long-term neuropathological effects in the rat brain following acute intoxication with diisopropylfluorophosphate. European Journal of Pharmacology, 2020, 886, 173538.	3.5	21
25	Modulation of Lymphocyte Potassium Channel K_V1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin. ACS Pharmacology and Translational Science, 2020, 3, 720-736.	4.9	18
26	Biophysical basis for Kv1.3 regulation of membrane potential changes induced by <scp>P2X4</scp>â€mediated calcium entry in microglia. Glia, 2020, 68, 2377-2394.	4.9	43
27	Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis. PLoS ONE, 2020, 15, e0222619.	2.5	3
28	Blocking Kv1.3 potassium channels prevents postoperative neuroinflammation and cognitive decline without impairing wound healing in mice. British Journal of Anaesthesia, 2020, 125, 298-307.	3.4	24
29	Comparison of the toxicokinetics of the convulsants picrotoxinin and tetramethylenedisulfotetramine (TETS) in mice. Archives of Toxicology, 2020, 94, 1995-2007.	4.2	10
30	Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinsonâ€™s disease. Journal of Clinical Investigation, 2020, 130, 4195-4212.	8.2	50
31	New capsaicin analogs as molecular rulers to define the permissive conformation of the mouse TRPV1 ligand-binding pocket. ELife, 2020, 9, .	6.0	10
32	The Trials and Tribulations of Structure Assisted Design of KCa Channel Activators. Frontiers in Pharmacology, 2019, 10, 972.	3.5	12
33	Assessing the Effects of Cytoprotectants on Selective Neuronal Loss, Sensorimotor Deficit and Microglial Activation after Temporary Middle Cerebral Occlusion. Brain Sciences, 2019, 9, 287.	2.3	4
34	Extracellular K⁺Dampens T Cell Functions: Implications for Immune Suppression in the Tumor Microenvironment. Bioelectricity, 2019, 1, 169-179.	1.1	17
35	Recent advances in our understanding of the structure and function of more unusual cation channels. F1000Research, 2019, 8, 123.	1.6	6
36	Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2019, 6, 723-738.	3.7	45

#	Article	IF	Citations
37	Radiation Increases Functional KCa3.1 Expression and Invasiveness in Glioblastoma. Cancers, 2019, 11, 279.	3.7	17
38	Antibodies and venom peptides: new modalities for ion channels. Nature Reviews Drug Discovery, 2019, 18, 339-357.	46.4	119
39	In Vivo Targeting of the Endothelium to Improve Vascular Function in a Rodent Model of Type 2 Diabetes. FASEB Journal, 2019, 33, 685.2.	0.5	0
40	Prolonged Administration of the KCa Channel Activator SKAâ€31 Improves Cardiac Function and Blood Pressure in Type 2 Diabetic Gotoâ€Kakizaki Rats. FASEB Journal, 2019, 33, 683.3.	0.5	0
41	Targeting potassium channels to treat cerebellar ataxia. Annals of Clinical and Translational Neurology, 2018, 5, 297-314.	3.7	50
42	A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3. MAbs, 2018, 10, 636-650.	5.2	16
43	Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Annals of Clinical and Translational Neurology, 2018, 5, 147-161.	3.7	39
44	Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimerâ€™s disease: preclinical proof of concept. Brain, 2018, 141, 596-612.	7.6	79
45	GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Archives of Toxicology, 2018, 92, 833-844.	4.2	12
46	The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. British Journal of Cancer, 2018, 118, 200-212.	6.4	58
47	Alpha1-adrenergic stimulation selectively enhances endothelium-mediated vasodilation in rat cremaster arteries. Physiological Reports, 2018, 6, e13703.	1.7	12
48	Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma. Scientific Reports, 2018, 8, 7654.	3.3	19
49	The voltageâ€gated potassium channel Kv1.3 is required for microglial proâ€inflammatory activation in vivo. Glia, 2018, 66, 1881-1895.	4.9	69
50	Ca2+-activated K+ channels modulate microglia affecting motor neuron survival in hSOD1G93A mice. Brain, Behavior, and Immunity, 2018, 73, 584-595.	4.1	18
51	Suppression of connexin 43 phosphorylation promotes astrocyte survival and vascular regeneration in proliferative retinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5934-E5943.	7.1	34
52	KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma. Current Neuropharmacology, 2018, 16, 618-626.	2.9	31
53	Structure Assisted Design of Small Molecule KCa Channel Modulators. FASEB Journal, 2018, 32, 556.1.	0.5	0
54	Chronic administration of an endothelial KCa channel activator (SKAâ€31) improves agonist evoked vasodilation in mesenteric arteries of aged rats. FASEB Journal, 2018, 32, 710.1.	0.5	0

#	Article	IF	Citations
55	BDE-47 and BDE-49 Inhibit Axonal Growth in Primary Rat Hippocampal Neuron-Glia Co-Cultures via Ryanodine Receptor-Dependent Mechanisms. Toxicological Sciences, 2017, 156, kfw259.	3.1	18
56	Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatric Diabetes, 2017, 18, 356-366.	2.9	18
57	Potassium channel expression and function in microglia: Plasticity and possible species variations. Channels, 2017, 11, 305-315.	2.8	44
58	Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Molecular Pharmacology, 2017, 91, 392-402.	2.3	39
59	Development of Tetramethylenedisulfotetramine (TETS) Hapten Library: Synthesis, Electrophysiological Studies, and Immune Response in Rabbits.. Chemistry - A European Journal, 2017, 23, 8466-8472.	3.3	17
60	Rapid Throughput Analysis of GABA_A Receptor Subtype Modulators and Blockers Using DiSBAC₁(3) Membrane Potential Red Dye. Molecular Pharmacology, 2017, 92, 88-99.	2.3	18
61	International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacological Reviews, 2017, 69, 1-11.	16.0	85
62	A multi-tiered, in vivo, quantitative assay suite for environmental disruptors of thyroid hormone signaling. Aquatic Toxicology, 2017, 190, 1-10.	4.0	17
63	Hydroxy-fipronil is a new urinary biomarker of exposure to fipronil. Environment International, 2017, 103, 91-98.	10.0	18
64	Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121). Molecular Pharmacology, 2017, 92, 469-480.	2.3	14
65	Are there superagonists for calcium-activated potassium channels?. Channels, 2017, 11, 504-506.	2.8	2
66	Differential Kv1.3, KCa3.1, and Kir2.1 expression in â€œclassicallyâ€•and â€œalternativelyâ€•activated microglia. Glia, 2017, 65, 106-121.	4.9	122
67	Structural insights into the potency of SK channel positive modulators. Scientific Reports, 2017, 7, 17178.	3.3	22
68	Inhibition of Soluble Epoxide Hydrolase as a Novel Approach to High Dose Diazepam Induced Hypotension. , 2016, 6, .		14
69	Vascular Reactivity Profile of Novel K_{Ca}3.1â€Selective Positiveâ€Gating Modulators in the Coronary Vascular Bed. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 184-192.	2.5	6
70	A Metal-Free Method for Producing MRI Contrast at Amyloid-Î². Journal of Alzheimer's Disease, 2016, 55, 1667-1681.	2.6	9
71	Models to identify treatments for the acute and persistent effects of seizureâ€inducing chemical threat agents. Annals of the New York Academy of Sciences, 2016, 1378, 124-136.	3.8	24
72	KCa3.1â^'/â^'Mice Do Not Develop CIA: Regulatory Role for KCa3.1 in Autoimmune Arthritis. Journal of Cellular Physiology, 2016, 231, 2313-2314.	4.1	6

#	Article	IF	Citations
73	Diisopropylfluorophosphate Impairs the Transport of Membrane-Bound Organelles in Rat Cortical Axons. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 645-655.	2.5	34
74	Chasing the Elusive Benzofuran Impurity of the THR Antagonist NH-3: Synthesis, Isotope Labeling, and Biological Activity. Journal of Organic Chemistry, 2016, 81, 1870-1876.	3.2	16
75	The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 2146-2161.	4.3	84
76	A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model. Vascular Pharmacology, 2016, 79, 24-31.	2.1	14
77	KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget, 2016, 7, 30781-30796.	1.8	44
78	Interrogation of the intersubunit interface of the open Hv1 proton channel with a probe of allosteric coupling. Scientific Reports, 2015, 5, 14077.	3.3	25
79	Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels. Journal of Cardiovascular Pharmacology, 2015, 66, 118-127.	1.9	19
80	Recent developments in ion channel pharmacology. Channels, 2015, 9, 335-335.	2.8	6
81	Dysregulation of Glutamine Transporter SNAT1 in Rett Syndrome Microglia: A Mechanism for Mitochondrial Dysfunction and Neurotoxicity. Journal of Neuroscience, 2015, 35, 2516-2529.	3.6	71
82	Rapid Throughput Analysis Demonstrates that Chemicals with Distinct Seizurogenic Mechanisms Differentially Alter Ca²⁺ Dynamics in Networks Formed by Hippocampal Neurons in Culture. Molecular Pharmacology, 2015, 87, 595-605.	2.3	29
83	Pharmacological gating modulation of small- and intermediate-conductance Ca²⁺-activated K⁺channels (K_{Ca}2.x and K_{Ca}3.1). Channels, 2015, 9, 336-343.	2.8	52
84	Human lung myofibroblast TGFÎ²1-dependent Smad2/3 signalling is Ca2+-dependent and regulated by KCa3.1 K+ channels. Fibrogenesis and Tissue Repair, 2015, 8, 5.	3.4	40
85	The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed KCa2 Activator and NaV Blocker, is a Potent Novel Anticonvulsant. Neurotherapeutics, 2015, 12, 234-249.	4.4	33
86	A Novel Pan-Negative-Gating Modulator of K_{Ca}2/3 Channels, Fluoro-Di-Benzoate, RA-2, Inhibits Endothelium-Derived Hyperpolarizationâ€“Type Relaxation in Coronary Artery and Produces Bradycardia In Vivo. Molecular Pharmacology, 2015, 87, 338-348.	2.3	19
87	Ion Channels in Innate and Adaptive Immunity. Annual Review of Immunology, 2015, 33, 291-353.	21.8	541
88	Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability. Journal of Neuroscience, 2015, 35, 11292-11307.	3.6	93
89	Bloodâ€“Brain Barrier KCa3.1 Channels. Stroke, 2015, 46, 237-244.	2.0	57
90	Novel Negative Gating Modulators of KCa2/3 as Pharmacological Tools for Novel Treatments. FASEB Journal, 2015, 29, 943.2.	0.5	0

#	Article	IF	Citations
91	Nanomolar Bifenthrin Alters Synchronous Ca²⁺Oscillations and Cortical Neuron Development Independent of Sodium Channel Activity. Molecular Pharmacology, 2014, 85, 630-639.	2.3	41
92	Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis â€“ Xenograft model. Journal of Autoimmunity, 2014, 55, 63-72.	6.5	58
93	New Positive Ca²⁺-Activated K⁺ Channel Gating Modulators with Selectivity for K_{Ca}3.1. Molecular Pharmacology, 2014, 86, 342-357.	2.3	50
94	Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Human Molecular Genetics, 2014, 23, 6848-6862.	2.9	66
95	Alterations in cerebellar physiology are associated with a stiff-legged gait in Atcayji-hes mice. Neurobiology of Disease, 2014, 67, 140-148.	4.4	20
96	Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, 1378-1391.	1.3	45
97	Kv1.3 channelâ€blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB Journal, 2014, 28, 3952-3964.	0.5	76
98	Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy. Journal of Medicinal Chemistry, 2014, 57, 7016-7030.	6.4	81
99	A pharmacologic activator of endothelial KCa channels enhances coronary flow in the hearts of type 2 diabetic rats. Journal of Molecular and Cellular Cardiology, 2014, 72, 364-373.	1.9	24
100	Positive KCa channel gating modulators with selectivity for KCa3.1 (1057.6). FASEB Journal, 2014, 28, .	0.5	1
101	The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion on Therapeutic Targets, 2013, 17, 1203-1220.	3.4	42
102	The Intermediate Conductance Calcium-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling. Journal of Biological Chemistry, 2013, 288, 15843-15853.	3.4	74
103	SKA-31, a novel activator of SKCa and IKCa channels, increases coronary flow in male and female rat hearts. Cardiovascular Research, 2013, 97, 339-348.	3.8	29
104	Ca²⁺-Activated K⁺ Channelâ€“3.1 Blocker TRAM-34 Attenuates Airway Remodeling and Eosinophilia in a Murine Asthma Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 212-219.	2.9	30
105	Development of a QPatch Automated Electrophysiology Assay for Identifying KCa3.1 Inhibitors and Activators. Assay and Drug Development Technologies, 2013, 11, 551-560.	1.2	16
106	Activation of <scp>K_{Ca}</scp>3.1 by <scp>SKA</scp>â€31 induces arteriolar dilatation and lowers blood pressure in normoâ€and hypertensive connexin40â€deficient mice. British Journal of Pharmacology, 2013, 170, 293-303.	5.4	43
107	Endothelial Small-Conductance and Intermediate-Conductance KCa Channels. Journal of Cardiovascular Pharmacology, 2013, 61, 102-112.	1.9	88
108	The Potassium Channel KCa3.1 as New Therapeutic Target for the Prevention of Obliterative Airway Disease. Transplantation, 2013, 95, 285-292.	1.0	19

#	Article	IF	Citations
109	The Ca2+-Activated K+ Channel KCa3.1 as a Potential New Target for the Prevention of Allograft Vasculopathy. PLoS ONE, 2013, 8, e81006.	2.5	18
110	The K+ Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis. PLoS ONE, 2013, 8, e85244.	2.5	43
111	Novel Phenolic Inhibitors of Small/Intermediate-Conductance Ca2+-Activated K+ Channels, KCa3.1 and KCa2.3. PLoS ONE, 2013, 8, e58614.	2.5	25
112	KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma. PLoS ONE, 2013, 8, e66886.	2.5	28
113	Blocking KCa3.1 Channels Increases Tumor Cell Killing by a Subpopulation of Human Natural Killer Lymphocytes. PLoS ONE, 2013, 8, e76740.	2.5	45
114	The Kv1.3 Blocker PAPâ€1 Reduces Infarction and Neurological Deficit in a Rat Model of Reperfusion Stroke. FASEB Journal, 2013, 27, .	0.5	1
115	Rosetta modeling of the inner KCa3.1 pore, a hotspot for small molecule modulation. FASEB Journal, 2013, 27, 913.23.	0.5	0
116	SKAâ€31, a positive modulator of SK Ca and IK Ca channels, increases systemic conductance and lowers arrterial pressure in an anesthetized pig model. FASEB Journal, 2013, 27, 900.7.	0.5	0
117	SKAâ€111, a positive KCa channel gating modulator with selectivity for KCa3.1. FASEB Journal, 2013, 27, 913.22.	0.5	0
118	Structureâ€“activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7106-7109.	2.2	11
119	Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimerâ€™s Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	2.0	53
120	Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. British Journal of Pharmacology, 2012, 165, 223-234.	5.4	60
121	Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): The first member of a new Î²-KTX subfamily. Biochemical Pharmacology, 2012, 83, 1307-1317.	4.4	32
122	Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon, 2012, 59, 529-546.	1.6	203
123	Genetic KCa3.1-Deficiency Produces Locomotor Hyperactivity and Alterations in Cerebral Monoamine Levels. PLoS ONE, 2012, 7, e47744.	2.5	49
124	NS6180, a new KCa3.1 blocker, inhibits Tâ€cell activation and dampens inflammation in a rat model of inflammatory bowel disease. FASEB Journal, 2012, 26, 695.12.	0.5	0
125	SKAâ€31, an enhancer of SK Ca and IK Ca channels, increases coronary flow in normotensive rats. FASEB Journal, 2012, 26, 857.3.	0.5	0
126	Does microglial dysfunction play a role in autism and Rett syndrome?. Neuron Glia Biology, 2011, 7, 85-97.	1.6	43

#	Article	IF	Citations
127	Amyloid-Î² Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity. Journal of Biological Chemistry, 2011, 286, 3693-3706.	3.4	234
128	The KCa3.1 Blocker TRAM-34 Reduces Infarction and Neurological Deficit in a Rat Model of Ischemia/Reperfusion Stroke. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2363-2374.	4.3	92
129	The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression. Drug Development Research, 2011, 72, 573-584.	2.9	88
130	Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3. Journal of Neuroscience, 2011, 31, 13002-13014.	3.6	190
131	Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels. Molecular Pharmacology, 2011, 79, 899-909.	2.3	48
132	Negative gating modulation by NS8593 depends on residues in the inner pore vestibule. FASEB Journal, 2011, 25, 1042.15.	0.5	0
133	Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Drug Development and Industrial Pharmacy, 2010, 36, 563-569.	2.0	12
134	Potassium Channel Block by a Tripartite Complex of Two Cationophilic Ligands and a Potassium Ion. Molecular Pharmacology, 2010, 78, 588-599.	2.3	29
135	Inhibition of the K⁺channel KCa3.1 ameliorates T cellâ€“mediated colitis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1541-1546.	7.1	136
136	Vascular K_{Ca}-channels as therapeutic targets in hypertension and restenosis disease. Expert Opinion on Therapeutic Targets, 2010, 14, 143-155.	3.4	83
137	Therapeutic potential of K_{Ca}3.1 blockers: recent advances and promising trends. Expert Review of Clinical Pharmacology, 2010, 3, 385-396.	3.1	172
138	Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opinion on Therapeutic Patents, 2010, 20, 1759-1765.	5.0	8
139	Endothelial KCa ion channels: their compartmentation in caveolae and relevance to cardiovascular pathologies. FASEB Journal, 2010, 24, 784.3.	0.5	0
140	Potassium Channel Block by a Tripartite Complex of Neutral Ligands with a Potassium Ion. FASEB Journal, 2010, 24, 770.3.	0.5	0
141	Renal fibrosis is attenuated by targeted disruption of K _{Ca} 3.1 potassium channels. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14518-14523.	7.1	140
142	Genetic Deficit of SK3 and IK1 Channels Disrupts the Endothelium-Derived Hyperpolarizing Factor Vasodilator Pathway and Causes Hypertension. Circulation, 2009, 119, 2323-2332.	1.6	215
143	Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure. Molecular Pharmacology, 2009, 75, 281-295.	2.3	188
144	Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery, 2009, 8, 982-1001.	46.4	644

#	Article	IF	Citations
145	The K⁺ channels K_{Ca}3.1 and K_v1.3 as novel targets for asthma therapy. British Journal of Pharmacology, 2009, 157, 1330-1339.	5.4	67
146	4-Phenoxybutoxy-substituted heterocycles â€“ A structureâ€“activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. European Journal of Medicinal Chemistry, 2009, 44, 1838-1852.	5.5	48
147	SKAâ€31, a new activator of KCa2 and KCa3.1 K+ channels, potentiates the EDHF response and lowers blood pressure. FASEB Journal, 2009, 23, 1018.6.	0.5	0
148	Genetic deficit of SK3 and IK1 channels abolishes EDHFâ€type vasodilation and elevates blood pressure.. FASEB Journal, 2009, 23, 1018.7.	0.5	0
149	K⁺ Channel Modulators for the Treatment of Neurological Disorders and Autoimmune Diseases. Chemical Reviews, 2008, 108, 1744-1773.	47.7	196
150	New Light on the â€œOldâ€•Chloride Channel Blocker DIDS. ACS Chemical Biology, 2008, 3, 399-401.	3.4	20
151	Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K ⁺ channel KCa3.1. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14442-14446.	7.1	102
152	KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney International, 2008, 74, 740-749.	5.2	71
153	The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. Journal of Clinical Investigation, 2008, 118, 3025-3037.	8.2	193
154	Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications. Current Medicinal Chemistry, 2007, 14, 1437-1457.	2.4	189
155	AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology, 2007, 45, 314-322.	7.3	76
156	Targeting Effector Memory T Cells with the Small Molecule Kv1.3 Blocker PAP-1 Suppresses Allergic Contact Dermatitis. Journal of Investigative Dermatology, 2007, 127, 1419-1429.	0.7	89
157	Targeting effector memory T-cells with Kv1.3 blockers. Current Opinion in Drug Discovery & Development, 2007, 10, 438-45.	1.9	30
158	A New Class of Blockers of the Voltage-Gated Potassium Channel Kv1.3 via Modification of the 4- or 7-Position of Khellinone. Journal of Medicinal Chemistry, 2006, 49, 1433-1441.	6.4	28
159	Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17414-17419.	7.1	470
160	Pharmacological Profiling of Orthochirus scrobiculosus Toxin 1 Analogs with a Trimmed N-Terminal Domain. Molecular Pharmacology, 2006, 69, 354-362.	2.3	38
161	PAPâ€1, a Selective Small Molecule Kv1.3 Blocker. FASEB Journal, 2006, 20, A326.	0.5	0
162	Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases. Molecular Pharmacology, 2005, 68, 1254-1270.	2.3	190

#	Article	IF	Citations
163	Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases. Molecular Pharmacology, 2005, 67, 1369-1381.	2.3	232
164	International Union of Pharmacology. LII. Nomenclature and Molecular Relationships of Calcium-Activated Potassium Channels. Pharmacological Reviews, 2005, 57, 463-472.	16.0	540
165	The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11094-11099.	7.1	172
166	K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochemical Journal, 2005, 385, 95-104.	3.7	103
167	Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases. Current Medicinal Chemistry, 2004, 11, 3041-3052.	2.4	77
168	K+ Channel Expression during B Cell Differentiation: Implications for Immunomodulation and Autoimmunity. Journal of Immunology, 2004, 173, 776-786.	0.8	175
169	Kv1.3-Blocking 5-Phenylalkoxypsoralens: A New Class of Immunomodulators. Molecular Pharmacology, 2004, 65, 1364-1374.	2.3	126
170	Khellinone Derivatives as Blockers of the Voltage-Gated Potassium Channel Kv1.3:â€‰ Synthesis and Immunosuppressive Activity. Journal of Medicinal Chemistry, 2004, 47, 2326-2336.	6.4	56
171	K+ channels as targets for specific immunomodulation. Trends in Pharmacological Sciences, 2004, 25, 280-289.	8.7	404
172	Blockade of the Intermediate-Conductance Calcium-Activated Potassium Channel as a New Therapeutic Strategy for Restenosis. Circulation, 2003, 108, 1119-1125.	1.6	217
173	International Union of Pharmacology. XLI. Compendium of Voltage-Gated Ion Channels: Potassium Channels. Pharmacological Reviews, 2003, 55, 583-586.	16.0	358
174	A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel Up-regulation in Chronically Activated T Lymphocytes. Journal of Biological Chemistry, 2003, 278, 9928-9937.	3.4	80
175	The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. Journal of Clinical Investigation, 2003, 111, 1703-1713.	8.2	368
176	Potassium channels as therapeutic targets for autoimmune disorders. Current Opinion in Drug Discovery & Development, 2003, 6, 640-7.	1.9	60
177	Modulation of Mouse Paneth Cell Î±-Defensin Secretion by mIKCa1, a Ca2+-activated, Intermediate Conductance Potassium Channel. Journal of Biological Chemistry, 2002, 277, 3793-3800.	3.4	90
178	Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). European Journal of Human Genetics, 2002, 10, 36-43.	2.8	32
179	Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon, 2001, 39, 1269-1276.	1.6	66
180	Calcium-activated Potassium Channels Sustain Calcium Signaling in T Lymphocytes. Journal of Biological Chemistry, 2001, 276, 12249-12256.	3.4	155

#	Article	IF	Citations
181	Design and Characterization of a Highly Selective Peptide Inhibitor of the Small Conductance Calcium-activated K+Channel, SkCa2. Journal of Biological Chemistry, 2001, 276, 43145-43151.	3.4	106
182	Molecular properties and physiological roles of ion channels in the immune system. Journal of Clinical Immunology, 2001, 21, 235-252.	3.8	212
183	Delineation of the Clotrimazole/TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1. Journal of Biological Chemistry, 2001, 276, 32040-32045.	3.4	128
184	Up-regulation of the IKCa1 Potassium Channel during T-cell Activation. Journal of Biological Chemistry, 2000, 275, 37137-37149.	3.4	357
185	Alkoxypsoralens, Novel Nonpeptide Blockers ofShaker-Type K+Channels:Â Synthesis and Photoreactivity. Journal of Medicinal Chemistry, 1998, 41, 4542-4549.	6.4	51